NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Recommendation of “Moderate Buy” by Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been given a consensus rating of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $38.25.

NRXP has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Friday, May 8th. BTIG Research restated a “buy” rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday, March 24th. Ascendiant Capital Markets lifted their price target on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, June 14th. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, April 27th.

Institutional Investors Weigh In On NRx Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Ethos Financial Group LLC increased its position in shares of NRx Pharmaceuticals by 33.6% during the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after acquiring an additional 4,000 shares in the last quarter. AdvisorShares Investments LLC lifted its position in NRx Pharmaceuticals by 28.2% in the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after acquiring an additional 92,463 shares in the last quarter. Anson Funds Management LP lifted its position in NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after acquiring an additional 1,018,853 shares in the last quarter. State Street Corp boosted its stake in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after purchasing an additional 10,700 shares during the last quarter. Finally, Commonwealth Equity Services LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter valued at $994,000. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ NRXP opened at $3.87 on Friday. The company has a 50 day simple moving average of $3.59 and a two-hundred day simple moving average of $2.65. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $5.05. The company has a market capitalization of $140.21 million, a price-to-earnings ratio of -3.55 and a beta of 2.19.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $19.43 million. On average, analysts forecast that NRx Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.